

School of Biomedical Science

**Bachelor of Science Honours in Healthcare and Clinical Research
Semester End Examination - Jun 2024**

**Duration : 180 Minutes
Max Marks : 100**

Sem II - Q1UF201T - Regulatory Affairs-I*General Instructions*

Answer to the specific question asked

Draw neat, labelled diagrams wherever necessary

Approved data hand books are allowed subject to verification by the Invigilator

- | | | |
|-----|--|--------|
| 1) | Define the Adverse Event. | K1(2) |
| 2) | Explain the ICMR and indian GCP. | K2(4) |
| 3) | Explain the bioavailability (BA) Trials. | K2(6) |
| 4) | Illustrate the responsibilities of USFDA. | K3(9) |
| 5) | Illustrate the documents retrieval and archival process. | K3(9) |
| 6) | Examine the EMEA. | K5(10) |
| 7) | Analyze the importance of Phase IV Clinical Trial. | K4(12) |
| 8) | Examine the European medicine agency (EMA) guidelines. | K5(15) |
| 9) | Examine the thalidomide disaster and Kafaivers Harris amendment act. | K5(15) |
| 10) | Elaborate the phase III and phase 4 clinical research. | K6(18) |